Abstract
Metastatic urothelial carcinoma (mUC) is an aggressive disease with few available therapeutics until recent approval of immune checkpoint inhibitors (ICI), fibroblast growth factor inhibitor receptor inhibitors and antibody-drug conjugate. Nevertheless, some patients do not respond to these treatments and predictive biomarkers are needed, especially for ICI.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
